TABLE 4
FROM:
Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole
D Saltzstein, P Sieber, T Morris and J Gallo
BACK TO ARTICLETable 4. Summary of changes in prostate-specific antigen and hormone levels at 3 months after randomization in the clinical trial
| Tamoxifen 20 mg plusbicalutamide 150 mg | Anastrozole 1 mg plusbicalutamide 150 mg | |
|---|---|---|
| Prostate-specific antigen (ng/ml) | ||
| Mean absolute change (s.d.) | -1.67 (5.22) | -0.59 (1.98) |
| Mean % change | -24.4 | -16.7 |
| Testosterone (nmol/l) | ||
| Mean absolute change (s.d.) | 20.53 (12.86) | 16.20 (7.26) |
| Mean % change | 162.8 | 124.3 |
| Estradiol, pmol/l | ||
| Mean absolute change (s.d.) | 213.78 (281.84) | 34.41 (39.64) |
| Mean % change | 314.7 | 54.6 |
| Luteinizing hormone (IU/l) | ||
| Mean absolute change (s.d.) | 11.22 (7.54) | 7.10 (4.01) |
| Mean % change | 257.8 | 182.1 |
| Follicle-stimulating hormone (IU/l) | ||
| Mean absolute change (s.d.) | 5.13 (5.60) | 0.82 (13.95) |
| Mean % change | 40.9 | 72.8 |
Sex hormone binding globulin ( mol/l)
| ||
| Mean absolute change (s.d.) | 0.03 (0.03) | 0.01 (0.01) |
| Mean % change | 48.5 | 17.7 |
s.d., standard deviation.
